Adaptive Biotechnologies Stock

adaptivebiotech.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $561.37MM

Adaptive Biotechnologies is a biotechnology company specializing immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Adaptive Biotechnologies before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Private Market Pricing DetailsValuation & Financings

Adaptive Biotechnologies Stock Price

Forge Price 1
Price no longer available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Adaptive Biotechnologies Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
01/04/2018 Series F-1 $45MM $xx.xx $1.35B Microsoft
Price per Share
$xx.xx
Shares Outstanding
4,217,985
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Microsoft
05/06/2015 Series F $195.1MM $xx.xx $1.08B Matrix Capital Management, Alexandria Real Estate Equities, BD Biosciences, Celgene, Foresite Capital Management, Illumina, Laboratory Corporation of America, Matrix Capital Management, Rock Springs Capital, Senator Investment Group, Tiger Global Management, Casdin Capital, Viking Global Investors
Price per Share
$xx.xx
Shares Outstanding
21,761,676
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Matrix Capital Management, Alexandria Real Estate Equities, BD Biosciences, Celgene, Foresite Capital Management, Illumina, Laboratory Corporation of America, Matrix Capital Management, Rock Springs Capital, Senator Investment Group, Tiger Global Management, Casdin Capital, Viking Global Investors
01/22/2015 Series E1 $105.12MM $xx.xx $652.13MM Undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
17,407,441
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed investors
01/21/2015 Series E $93.75MM $xx.xx $321.37MM Undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
15,524,350
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed investors
07/29/2014 Series D $107MM $xx.xx $261.89MM Viking Global Investors
Price per Share
$xx.xx
Shares Outstanding
19,269,117
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Viking Global Investors
07/09/2013 Series C $5.02MM $xx.xx $76.08MM Viking Global Investors, Ares Capital
Price per Share
$xx.xx
Shares Outstanding
1,905,206
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Viking Global Investors, Ares Capital
06/02/2011 Series B $5.82MM $xx.xx $49.04MM Angel investors
Price per Share
$xx.xx
Shares Outstanding
3,399,033
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Angel investors
03/24/2010 Series A $4.55MM $xx.xx $27.52MM Undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
4,550,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed investors

Adaptive Biotechnologies stock FAQs

plusminus

Can you buy Adaptive Biotechnologies stock?

You can no longer buy Adaptive Biotechnologies stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Adaptive Biotechnologies stock?

You can no longer buy Adaptive Biotechnologies stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Adaptive Biotechnologies stock?

You can no longer sell stock of Adaptive Biotechnologies on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Adaptive Biotechnologies stock?

You can no longer sell stock of Adaptive Biotechnologies on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Adaptive Biotechnologies a public company?

Adaptive Biotechnologies is now a public company traded on NASDAQ with ticker ADPT.
plusminus

What is Adaptive Biotechnologies’ stock price?

The stock price of Adaptive Biotechnologies is $4.07 as of 1/18/24.
plusminus

What is Adaptive Biotechnologies’ stock ticker symbol?

The ticker symbol of Adaptive Biotechnologies is ADPT.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Adaptive Biotechnologies investors also invested in these private companies

Alexandria Real Estate Equities
Laboratory Corporation Of America
Bd Biosciences

Leadership & Board

Leadership

JULIE RUBINSTEIN
President
SEAN NOLAN
Chief Technical Officer
CHAD ROBINS
Chief Executive Officer, Co-founder
LANCE BALDO
Chief Medical Officer
HARLAN ROBINS, PHD
Chief Scientific Officer, Co-founder
CHAD COHEN
Chief Financial Officer

Board

PETER NEUPERT
Operating Partner at Health Evolution Partners
MIKE PELLINI, MD
MICHELLE GRIFFIN
Adaptive Biotechnologies
ANDRIS ZOLTNERS
Self
KEVIN CONROY
DAVID GOEL
Matrix Capital Management
CHAD ROBINS
Adaptive Biotechnologies
ERIC DOBMEIER
Adaptive Biotechnologies
ROBERT HERSHBERG, MD, PhD
Celgene

Adaptive Biotechnologies’ news and media highlights

Fourth quarter sequencing revenue increased 81 percent to $23.1 million year over year, while development revenue dropped 15 percent to $14.9 million.
Adaptive Biotechnologies and Microsoft Partner To Decode COVID-19 Immune Response and Provide Open Data Access
Updated on: Nov 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.